Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of ONS-5010 for the treatment of wet age related macular degeneration (wet AMD)

Trial Profile

A clinical trial of ONS-5010 for the treatment of wet age related macular degeneration (wet AMD)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Dec 2018

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors Outlook Therapeutics
  • Most Recent Events

    • 18 Dec 2018 According to an Outlook Therapeutics media release, if the companys wet AMD clinical program (two adequate and well controlled studies for wet AMD-CT profile 301711 and 301714) is successful, it will support the companys plans to submit for regulatory approval in multiple markets in 2020.
    • 18 Dec 2018 According to an Outlook Therapeutics media release, this study is now over 50% enrolled.
    • 03 Dec 2018 According to an Outlook Therapeutics media release, Oncobiologics, Inc. changed its name to Outlook Therapeutics, Inc.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top